Section Arrow
XFOR.NASDAQ
- X4 Pharmaceuticals
Quotes are at least 15-min delayed:2024/05/16 10:48 EDT
Last
 0.9699
-0.0063 (-0.65%)
Day High 
0.9897 
Prev. Close
0.9762 
1-M High
1.39 
Volume 
262.90K 
Bid
0.9699
Ask
0.97
Day Low
0.955 
Open
0.9659 
1-M Low
0.9 
Market Cap 
163.94M 
Currency USD 
P/E -- 
%Yield
10-SMA 1.06 
20-SMA 1.13 
50-SMA 1.17 
52-W High 2.575 
52-W Low 0.5723 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.67/-0.21
Enterprise Value
221.12M
Balance Sheet
Book Value Per Share
0.01
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
JAGXJaguar Health0.2658+0.0107+4.19%-- 
SCPXScorpius Holdings0.0975+0.0198+25.48%-- 
DNAGinkgo Bioworks Holdings0.8209-0.0182-2.17%-- 
NVAXNovavax12.7512-0.1488-1.15%-- 
NBYNovaBay Pharmaceuticals0.1037-0.0008-0.77%-- 
Quotes are at least 15-min delayed:2024/05/16 10:48 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditionsresulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.